Arcutis Biotherapeutics
ARQT
239 hedge funds and large institutions have $2.37B invested in Arcutis Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 88 increasing their positions, 83 reducing their positions, and 21 closing their positions.
294% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $2.77M
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
33% more capital invested
Capital invested by funds: $1.78B → $2.37B (+$590M)
4% more funds holding
Funds holding: 230 → 239 (+9)
6% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 83
1.68% less ownership
Funds ownership: 106.62% → 104.93% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
+$31.5M |
| 2 |
Jennison Associates
New York
|
+$18.1M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$13.1M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.54M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$5.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.8M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$16.7M |
| 3 |
Millennium Management
New York
|
-$12M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$9.23M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.88M |
ARQT Hedge Fund Activity: Q3 2025 in Review
239 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2025, worth a combined $2.37B — up 33% from $1.78B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ARQT positions and 21 closed out — a net gain of 13 holders — while 88 added to existing stakes and 83 trimmed.
The largest buyer was Perpetual Ltd, adding an estimated $31.5M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $20.8M sold.
- 239 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2025, up from 230 in Q2 2025.
- Funds reported $2.37B of Arcutis Biotherapeutics stock for Q3 2025, up 33% quarter-over-quarter.
- 34 funds opened new Arcutis Biotherapeutics positions in Q3 2025 and 21 closed out, a net change of +13 holders.
- The largest Arcutis Biotherapeutics buyer in Q3 2025 was Perpetual Ltd, an estimated $31.5M added.
- The largest Arcutis Biotherapeutics seller in Q3 2025 was Point72 Asset Management, an estimated $20.8M sold.
Based on aggregated 13F filings for Q3 2025.